Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 7Non-Muscle Invasive Bladder Neoplasms 5Carcinoma, Transitional Cell 2Urothelial Carcinoma of the Bladder 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Rectal Neoplasms 1Peritoneal Neoplasms 1Peritoneal Diseases 1Neoplasms by Site 1Neoplasms 1Male Urogenital Diseases 1HIV Infections 1Female Urogenital Diseases 1Colorectal Neoplasms 1Appendiceal Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 1enfortumab vedotin 1Radiation Dose Hypofractionation 1Mitomycin 1Gemcitabine 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Diseases × Mitomycin × 30 days × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡